The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS)

Authors :: Andrew J. Wagner
Cassandra Choe-Juliak
Neeta Somaiah
Mrinal M. Gounder
Scott H. Okuno
Sharon Shacham
Gary K. Schwartz
Michael Kauffman
Lee D. Cranmer
Steven Attia
Mohammed M. Milhem
Sant P. Chawla
Richard F. Riedel
Albiruni Ryan Abdul Razak
Source :: Journal of Clinical Oncology. 34:TPS11072-TPS11072
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: TPS11072Background: DDLS represents progression from low- to high-grade non-lipogenic morphology within well-differentiated liposarcoma (WDLS) with the potential to metastasize and a higher mortali...

Tools